Source - SMW
Destiny Pharma hailed 'positive' results from an independent study showing that the company's drug to combat antimicrobial resistance had met its primary objective. 

In addition to the study reporting a favourable safety and local tolerability profile of the nasal gel formulation (the primary objective), the study also noted, as expected, that exposure to company's antimicrobial resistance drug, XF-73, produced a rapid reduction in levels of nasal S. aureus in all patients included in the trial, the company said. 

The clinical stud underscores 'our confidence in the potential of XF-73 as a novel treatment to prevent the occurrence of post-surgical S. aureus bacterial infections,' Destiny said.

'We look forward to reporting headline data in mid-2020 from our ongoing 200 patient phase 2b trial that is assessing the ability of XF-73 to reduce nasal levels of S. aureus in patients at high risk of infection that are undergoing surgery,' it added. 


At 8:58am: (LON:DEST) Destiny Pharma Plc share price was +1.5p at 41.5p



Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account.